TABLE 3.
Progression‐free survival and overall survival in the TCGA groups of uterine carcinosarcoma, using the correspondent groups in the 2013 TCGA cohort as reference
| TCGA group (UCS vs 2013 TCGA cohort) | Progression‐free survival | Overall survival | ||||
|---|---|---|---|---|---|---|
| HR | 95% CI | P value | HR | 95% CI | P value | |
| POLEmut | NV a | NV | NV | NV | NV | NV |
| MMRd | 0.75 | 0.26–2.19 | 0.595 | 5.90 | 2.19–15.86 | <0.001 |
| NSMP | 5.31 | 2.44–11.59 | <0.001 | 22.02 | 6.90–70.27 | <0.001 |
| p53abn | 2.18 | 1.29–3.69 | 0.004 | 3.51 | 1.86–6.64 | <0.001 |
Abbreviations: CI, confidence interval; HR, hazard ratio; UCS, uterine carcinosarcoma.
a
NV, not evaluable, because no event occurred in POLEmut cases.